rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    IMNM
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Immunome: De-Risked With The FDA, With An Admirably Deep Clinical Bench (NASDAQ:IMNM)
      Nov 17Seeking AlphaIMNM
      Piper Sandler lowers Immunome stock price target to $30 on higher costs
      Nov 10Investing.comIMNM
      Immunome Analysts Cut Their Forecasts After Q3 Results
      Nov 10BenzingaIMNM
      Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Nov 6Yahoo FinanceIMNM
      Immunome stock may move 9.4% on earnings release
      Nov 6Investing.comIMNM
      Immunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026
      Nov 4Yahoo FinanceIMNM
      Immunome Stock Gets EMA Review For Desmoid Tumor Drug
      Nov 2Yahoo FinanceIMNM
      Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
      Nov 2Yahoo FinanceIMNM
      EMA validates Immunome application for desmoid tumor treatment
      Oct 30Investing.comIMNM
      Immunome stock price target maintained at $40 by H.C. Wainwright
      Oct 27Investing.comIMNM
      Immunome presents additional varegacestat trial data at ESMO
      Oct 26Investing.comIMNM
      Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026
      Oct 26Yahoo FinanceIMNM
      William Blair Initiates Coverage on Immunome With Outperform Rating
      Oct 16Yahoo FinanceIMNM
      William Blair initiates Immunome stock coverage with outperform rating
      Oct 16Investing.comIMNM
      Immunome (IMNM) Following FDA Clearance Is Its Oncology Story Back In Value Focus
      Oct 13Yahoo FinanceIMNM
      Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Oct 6Yahoo FinanceIMNM
      Immunome stock holds at Stifel as Bristol deal cleans up license
      Oct 6Investing.comIMNMSF
      Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), Pacira Pharmaceuticals (PCRX)

      Detailed price information for Pacira Pharm Inc (PCRX-Q) from The Globe and Mail including charting and trades.

      Oct 6The Globe and MailIMNM
      Immunome (IMNM) Is Down 6.5% After FDA Clears IND For Novel ADC IM-1340 Trial – Has The Bull Case Changed?
      Oct 2Yahoo FinanceIMNM
      Stifel Initiates Immunome at Hold With $24 Price Target

      Immunome (IMNM) has an average rating of buy and mean price target of $35.20, according to analysts

      Oct 1Yahoo FinanceIMNM
      Immunome (IMNM) Stock Looks Near Fair Value As Its 186% Run Continues

      Immunome has delivered a powerful multi year share price run, and the question now is whether the current US$21.51 price lines up with the cash flows that can support it. With the spotlight on its pipeline progress, the valuation story increasingly comes back to what the company’s future cash generation may justify. Immunome’s share price has gained 186.4% over the past 3 years, which puts a lot of weight on whether its cash flows can eventually back up that kind of move. The recent FDA...

      Oct 1Yahoo FinanceIMNM
      Stifel initiates Immunome stock coverage with Hold rating at $24
      Sep 30Investing.comIMNM
      Immunome receives FDA clearance for IM-1340 solid tumor trial
      Sep 30Investing.comIMNM
      Immunome Gets FDA Clearance for IM-1340 Clinical Trial in Advanced Solid Tumors
      Sep 30Yahoo FinanceIMNM
      Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
      Sep 30Yahoo FinanceIMNM
      Immunome at H.C. Wainwright conference: pipeline bets on ADCs
      Sep 14Investing.comIMNM
      Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE) and Immunome (IMNM)

      Detailed price information for Fortrea Holdings Inc (FTRE-Q) from The Globe and Mail including charting and trades.

      Sep 11The Globe and MailFTREIMNM
      Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference

      BOTHELL, Wash., September 02, 2026--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at H.C. Wainwright’s 28th Annual Global Investment Conference on September 14, 2026, at 11:00 a.m. ET.

      Sep 2Yahoo FinanceIMNM

      This is the newest page. Registered accounts read further back.